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Abstract
Wnt/b-catenin pathway controls biochemical processes related to cell differentiation. In committed cells the alteration of
this pathway has been associated with tumors as hepatocellular carcinoma or hepatoblastoma. The present study evaluated
the role of Wnt/b-catenin activation during human mesenchymal stem cells differentiation into hepatocytes. The
differentiation to hepatocytes was achieved by the addition of two different conditioned media. In one of them, b-catenin
nuclear translocation, up-regulation of genes related to the Wnt/b-catenin pathway, such as Lrp5 and Fzd3, as well as the
oncogenes c-myc and p53 were observed. While in the other protocol there was a Wnt/b-catenin inactivation. Hepatocytes
with nuclear translocation of b-catenin also had abnormal cellular proliferation, and expressed membrane proteins involved
in hepatocellular carcinoma, metastatic behavior and cancer stem cells. Further, these cells had also increased auto-renewal
capability as shown in spheroids formation assay. Comparison of both differentiation protocols by 2D-DIGE proteomic
analysis revealed differential expression of 11 proteins with altered expression in hepatocellular carcinoma. Cathepsin B and
D, adenine phosphoribosyltransferase, triosephosphate isomerase, inorganic pyrophosphatase, peptidyl-prolyl cis-trans
isomerase A or lactate dehydrogenase b-chain were up-regulated only with the protocol associated with Wnt signaling
activation while other proteins involved in tumor suppression, such as transgelin or tropomyosin b-chain were down-
regulated in this protocol. In conclusion, our results suggest that activation of the Wnt/b-catenin pathway during human
mesenchymal stem cells differentiation into hepatocytes is associated with a tumoral phenotype.
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Introduction
Wnt/b-catenin signaling pathway is a master regulator of cell
fate and proliferation during embryonic development that plays
a main role in the control of differentiation of embryonic and
adult stem cells [1]. A key element of this pathway is b-catenin,
a multifunctional protein with important functions in intracel-
lular adhesion, cell growth, survival and differentiation [2]. In
the canonical Wnt/b-catenin pathway, nuclear b-catenin is
associated with T cell factors and lymphoid enhancer-binding
factor1 leading to transcriptional activation of target genes that
regulate many cellular processes, such as cell cycle control
through c-myc or cellular differentiation [3]. Wnt/b-catenin is
activated during mesenchymal stem cells (MSC) differentiation
to osteoblasts [4] and inactivated during differentiation into
adipocytes [5]. Some studies have also recently documented the
inactivation of this pathway during differentiation of MSC into
hepatocytes [6,7,8]. The aberrant activation of Wnt/b-catenin
pathway in committed cells has been related with the
development of several types of tumors, including hepatocellular
carcinoma or hepatoblastoma [9,10,11]. The Wnt/b-catenin
pathway could be implicated in the mechanisms that participate
in the progression of functional differentiated hepatocytes into
tumor cells [10,11,12,13].
Stem cells and cancer are inextricable linked and emerging data
suggest an association between alterations in stem cells and the
generation of cancer stem cells (CSC) [14,15,16]. However, the
mechanisms by which stem cells adopt CSC properties are
presently unknown. In this context it is particularly interesting to
study the consequences of the activation of Wnt/b-catenin
pathway during MSC differentiation into hepatocytes and its
relationship with the occurrence of a tumoral phenotype. This
study examines the effects of Wnt/b-catenin activation during the
differentiation of MSC into hepatocytes as well as on the
association of Wnt/b-catenin pathway activation with the
generation of a tumoral phenotype.
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Immunophenotype of human mesenchymal stem cells
before and after differentiation into hepatocytes
Human MSCs specific markers were evaluated by flow
cytometry before and after 21 days of treatment with two
protocols (CM1 and CM2) of hepatocytes differentiation. At 0
days, undifferentiated human bone marrow MSCs were negative
for the expression of CD34, CD45, CD117, CD133, CD184 and
VEGFR2, but positive for the expression of CD13, CD26, CD29,
CD44, CD49e, CD90, CD105 and CD166 (Table 1). When
human MSCs were cultured during 21 days for hepatocytes
differentiation, marked differences in the levels of CD13, CD49e,
CD133, CD166 and VEGFR2 were observed in CM1 and CM2-
treated cells. The levels of these markers were significant higher in
CM2-treated cells as compared to undifferentiated cells or CM1-
treated cells (Figure 1).
Table 1. Stem cells/cancer stem cells markers expression in
undifferentiated cells at time 0 days.
Undifferentiated
cells (t=0)
% CD13 99.560.04
% CD29 99.860.11
% CD34 2.0260.158
% CD44 99.560.45
% CD45 1.1861.491
% CD49e 61.8613.09
% CD73 99.560.40
% CD90 99.660.13
% CD105 98.860.52
% CD133 1.3560.979
% CD166 67.9616.58
% CXCR4 0.9660.179
% VEGFR2 2.0460.311
Data are included as mean 6 standard deviation.
doi:10.1371/journal.pone.0034656.t001
Figure 1. Differential stem cells markers in undifferentiated and differentiated human mesenchymal stem cells. Levels of CD13,
CD49e, CD166, CD133 and VEGFR2 in undifferentiated cells (UC), CM1 and CM2-treated cells after 21 days of culture. (Conditioned medium: CM).
Values are expressed as mean of percentage 6 standard deviation. (a p,0.001 and b p,0.01 vs. CM1-treated cells; +++ p,0,001 and + p,0,05 vs.
undifferentiated cells).
doi:10.1371/journal.pone.0034656.g001
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mesenchymal stem cells during their differentiation into
hepatocytes
To compare the potential for hepatic differentiation of both
protocols, the expression of hepatospecific genes was evaluated
measuring mRNA levels by RT-PCR and protein expression by
immunocytochemistry. The mRNA levels of albumin (ALB), a-
fetoprotein (aFP), a1-antitrypsin (a1-AT), C/EBPa and CYP3A5
were strongly induced in human MSCs treated with CM1 or CM2
at 7, 14 and 21 days, compared to undifferentiated cells (UC).
Comparatively, at 21 days of differentiation, there are no
significant differences between both differentiation protocols. In
CM2-treated cells there were not significant differences in the
expression of these genes between cells to time 0 and cells after
48 h of treatment. The expressions of albumin and C/EBP were
bigger in CM1 than CM2-treated cells while the expressions of a1-
AT and CYP3A5 were increased in CM2 vs. CM1-tretaed cells.
The expression of aFP was similar with both protocols (Figure 2).
Expression of hepatospecific proteins, such as albumin, a1-
antitrypsin, a-fetoprotein and cytokeratin 19 were also immuno-
detected in cells after 21 days of differentiation with both protocols
CM1 or CM2 (Figure 3). Both protocols expressed with similar
intensity hepatospecific proteins. Undifferentiated cells at 21 days
were negative for the expression of these proteins. PAS stain was
positive after treatment with CM1 and CM2 although a higher
intensity was observed in cells cultured with CM2.
Role of Wnt/b-catenin pathway and p53 during human
mesenchymal stem cells differentiation into hepatocytes
Since Wnt/b-catenin pathway plays a main role in the control
of differentiation of adult stem cells, confocal microscopy was used
to study the subcellular localization of b-catenin during differen-
tiation into hepatocytes in both CM1 and CM2 (Figure 4A).
Immunofluorescence staining demonstrated that b-catenin local-
ized to the cell membrane or to the peri-membrane region in
undifferentiated and CM1 cells after 21 days, while there was no
evidence of nuclear translocation. In contrast, there was a clear
localization of b-catenin to the nuclei of differentiated human
MSCs after treatment with CM2.
To confirm Wnt/b-catenin pathway activation during CM2
protocol, the expression of several genes regulated by this pathway,
such as Lrp5/6, Frizzled 3 and c-myc, were next analyzed. The
Figure 2. The treatments with CM1 or CM2 increase the expression of hepatospecific genes in human mesenchymal stem cells.
Relative levels of mRNA expression of A) albumin (ALB), B) a-fetoprotein (aFP), C) a1-antitrypsin (a-1-AT), D) CCAAT/enhancer-binding protein beta
(C/EBP) and E) cytochrome P450 (CYP3A5) were determined in human undifferentiated mesenchymal stem cells before and after differentiation with
conditioned medium 1 (CM1) or 2 (CM2) after 7, 14 and 21 days of culture; Gene expression is shown as fold-changes compared to undifferentiated
cells at each time. Values are expressed as mean 6 standard deviation. All genes were increased significantly respect to undifferentiated cells (UC).
a
p,0.001,
b p,0.01 vs. CM1 or CM2.
doi:10.1371/journal.pone.0034656.g002
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increased the mRNA expression of Lrp5, Frizzled 3 and c-myc.
Conversely, undifferentiated cells and CM1-treated cells showed
much lower levels of expression of these genes (Figure 4B).
Figure 4c shows western blot of p53 and tubulin as loading
control. The expression of p53 was similar in undifferentiated and
CM1-treated cells however its expression was significantly reduced
in CM2-treated cells.
Wnt/b-catenin activation leads to abnormal proliferation
and spheroids formation
Figure 5a shows that after 14 days of hepatocytes differentiation
the number of CM2-treated cells begins to be higher with this
treatment than CM1-treated cells or undifferentiated cells. At 21
days of hepatocytes differentiation, in CM2-treated cells there was
a 75% more of cells than in undifferentiated or CM1-treated cells
(a p,0.001 vs. CM1-treated cells and undifferentiated cells at 14
days and 21 days).
Nuclear staining of PCNA was significantly higher in CM2-
treated cells than in undifferentiated or CM1-treated cells
(Figure 5b). PCNA staining reinforces the abnormal prolifera-
tion detected in CM2-treated cells. With respect to cell cycle,
Figure 5c shows a similar percentage of cells in G0/G1, G2/M
and S phase in undifferentiated cells and CM1-treated cells.
However in CM2-treated cells it is interesting to note a
significant increase in the percentage of cells in S phase as well
Figure 3. The treatment with CM1 or CM2 induces the presence of hepatospecific proteins in human mesenchymal stem cells. The
presence of hepatospecific proteins such as albumin, a 1-antitrypsin, a-fetoprotein, cytokeratin-19 and PAS stain were evaluated by
immunohistochemistry after 21 days of culture with conditioned medium CM1 or CM2. Arrows show positive staining area.
doi:10.1371/journal.pone.0034656.g003
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and CM1-treated cells.
For spheroid assay, differentiated cells for 21 days were cultured
in low adherent plates for 4 days. Primary spheroids were detected
in all groups although the number of spheres seemed be higher in
CM2-treated cells. To quantify this data spheres were digested
with trypsin-EDTA and subsequently counted. It is interesting to
note that the capability to form spheres and the number of cells
was higher in CM2-treated cells than the other cells (Figure 5d).
After 4 days more of culture in low adherence plates and a clonal
dilution the number of secondary spheres was significantly higher
in CM2-treated cells than in undifferentiated cells (+++ p,0.001)
and CM1-treated cells (a p,0.001). There was not difference in
the number of spheres between undifferentiated and CM1-treated
cells (Figure 5e). A detail of these secondary spheroids is showed in
the microphotographs of Figure 5f. 3D structure of spheroids is
showed in the movie of Supporting Information files (Figure S1).
3D animation of detected spheres was observed in each treatment;
however we show only an example of this 3D-structure in this case
a spheroid corresponding to CM2-treated cells.
Analysis of protein expression profile by DIGE
A proteomic DIGE approach was used to analyze the repertoire
of proteins differentially expressed in control cells and hepatocytes
obtained with CM1 or CM2 differentiation protocols. The DIGE
analysis showed 39 differentially expressed proteins, and 17 of
them were identified, including chaperones, metabolic, structural,
proteolytic and apoptosis-related proteins (Table 2). Eleven of
these proteins were differentially expressed in CM1 vs. CM2
(Figure 6). The differential expression in CM1 vs. CM2 of
proteins, such as adenine phosphoribosyl transferase, transgelin,
cathepsine B precursor, tropomyosin b chain and L-lactate
dehydrogenase b chain was confirmed by western blots
(Figure 5B). DIGE analysis showed a higher expression of adenine
phosphoribosyltransferase, cathepsin B and D, triosephosphate
isomerase, inorganic pyrophosphatase, peptidyl-prolyl cis-trans
isomerase A or L-lactate dehydrogenase b-chain in hepatocytes
obtained after treatment with CM2, than in CM1-treated or
undifferentiated cells. In contrast, the expression of other proteins,
such as transgelin, tropomyosin b chain, annexin A5 or Dna J
homologous subfamily B decreased in hepatocytes obtained after
treatment with CM2, compared to CM1-treated or undifferenti-
ated cells. Nuclear b-catenin was also more expressed after
treatment with CM2 than in CM1-treated cells.
Discussion
Hepatocytes differentiation has been achieved using different
types of stem cells, MSC [17], embryonic stem cells [18] or
induced pluripotent stem cells [19]. However in these studies the
role of Wnt/b-catenin activation during hepatogenesis is unclear.
In our study, we used human MSC and two different protocols to
achieve differentiation into hepatocytes; one without Wnt/b-
catenin activation (CM1) and other with Wnt signaling activation
(CM2). The expression of hepatospecific genes and the key
regulator of hepatogenesis CEBP were achieved in both protocols.
Similar differentiation results has been obtained by others authors
using other stem cells [20].
Wnt/b-catenin pathway activation took place in CM2-treated
cells, with nuclear b-catenin translocation and up-regulation of
genes related to this pathway. Treatment of cells with another
protocol (CM1) also induced hepatic differentiation but without
the concurrence activation of Wnt/b-catenin pathway. We show
for the first time the capability of CM1 (HGF+FGF7) to
Figure 4. The treatment of human mesenchymal stem cells with CM2 induces nuclear translocation ofb-catenin and Wnt signaling
activation. A) To determine b-catenin subcellular localization, human mesenchymal stem cells undifferentiated (UC) and treated with conditioned
medium 1 (CM1) or 2 (CM2) after 21 days of culture were stained for b-catenin immunofluorescence (green) and counterstained with DAPI (blue).
Merged image of b-catenin-FITC and DAPI staining is also shown. Original magnification: 406. B) mRNA expression of Lrp5/6, Frizzled- 3 (FZD3) and c-
myc was evaluated in undifferentiated cells and cells treated with conditioned medium 1 (CM1) or 2 (CM2). Fold of undifferentiated cells at 21 days of
culture.
a p,0.001 vs. CM1-treated cells. C) Figure 4 c shows western blot of p53 and a-tubulin as loading control. Image is representative of three
independent experiments.
doi:10.1371/journal.pone.0034656.g004
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that differentiation into hepatocytes may be induced with or
without activation of Wnt/b-catenin pathway. Our results with
CM1-treated cells are consistent with other studies where down-
regulation of Wnt/b-catenin pathway during hepatic differentia-
tion is observed [6,7,8]. On the other hand, in protocol CM2,
dexamethasone was administered, and the administration of high
dose of this glucocorticoid may be responsible of the nuclear b-
catenin translocation observed. Others authors have demonstrated
that equal concentration of dexamethasone induced osteogenesis
of murine MSC via nuclear b-catenin translocation [15]. These
data suggest that the down-regulation of this pathway is not
essential for the differentiation of human MSC into hepatocytes.
Therefore, in our hands the activation or inhibition of Wnt/b-
catenin signaling pathway did not lead the hepatogenesis of
human MSCs. However, the activation of Wnt signaling during
hepatocytes differentiation might be associated with the generation
of a tumoral phenotype and the expression of proteins related to
liver cancer. Wnt/b-catenin pathway has been involved in the
development, maintenance and differentiation of normal and
malignant liver progenitor cells or MSC [16]. The sequence of
molecular events leading to liver carcinogenesis is not well known.
The accumulation of genetic alterations driving a cirrhotic liver to
cancer is a multistep process originating from stem cells or mature
hepatocytes [21]. Adult human MSC may be targets for malignant
transformation and may undergo spontaneous transformation
after long-term in vitro culture, supporting the hypothesis that
some CSC originate from multipotential stem cells [22,23]. In vitro
data from transgenic mice suggest that activation of the Wnt/b-
catenin pathway in epidermal stem cells leads to epithelial cancers
[24]. The nuclear translocation of b-catenin in neoplastic
hepatocytes leads to retrodifferentiation into immature hepatocyte
progenitors [10]. Many in vivo studies have associated Wnt/b-
catenin pathway activation with hepatic tumoral processes, such as
Figure 5. Markers of tumoral phenotype. A) Number of cells after 7, 14 and 21 days of culture in undifferentiated, CM1 and CM2-treated cells.
Values expressed as mean 6 standard deviation. a p,0.001 vs. CM1-treated cells and undifferentiated cells. B) The presence of nuclear PCNA (brown
nucleus) was evaluated by immunohistochemistry after 21 days of culture in undifferentiated cells, CM and CM2-treated cells. Image is representative
of three experiments. Original magnification: 206. C) Cell cycle was analyzed at 21 days of hepatocyte differentiation in undifferentiated, CM1 and
CM2-tretaed cells. Data are showed as mean of percentage plus standard deviation. a p,0.001 vs. CM1-treated cells, ++ p,0.01 and +++ p,0.001 vs.
undifferentiated cells. D) Primary spheroid assay with count of number of cells after 4 days of culture with conditioned medium for spheroid
formation. Data are showed that mean 6 standard deviation (a p,0.001 vs. CM1-treated cells and +++ p,0.001 vs. undifferentiated cells). E)
Secondary spheroid formation assay. Number of secondary spheroids was counted in an inverted microscope. Three experiments were carried out
and data are expressed as mean 6 standard deviation (a p,0.001 vs. CM1-treated cells and +++ p,0.001 vs. undifferentiated cells). F) Detail of
secondary spheroids is showed in the microphotographs of undifferentiated cells, CM1 and CM2-treated cells.
doi:10.1371/journal.pone.0034656.g005
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deregulation of Wnt signaling has been implicated as a major
mechanism of liver tumorigenesis [27,28] and up-regulation of
Wnt signaling is a hallmark of hepatoblastoma, the predominant
hepatic neoplasm in infants and children. Wnt/b-catenin
activation has been found to be associated with increases in c-
myc and cyclin D1 staining in tumours of patients with
hepatoblastoma [29]. In the case of hepatocellular carcinoma
molecular alterations responsible for its development and
progression include: 1) loss of tumor suppressors genes, as p53
and/or activation of cyclin D1, 2) activation of oncoproteins as c-
myc, and 3) alterations in Wnt signaling leading to nuclear
accumulation of b-catenin [10,30]. Our results show that the
majority of these alterations (loss of p53, nuclear accumulation of
b-catenin or c-myc overexpression), are present, along with the
activation of Wnt signaling, in the hepatocytes obtained after CM2
treatment. Protein p53 is implicated in the control of cell cycle,
apoptosis, DNA repair and angiogenesis and deregulation of p53
favors the development of liver tumor [31]. The loss of p53 has
been described in many types of human tumors, particularly in
30%–60% of hepatocelular carcinoma contributing with the
tumor progression [32]. The increases of c-myc observed in
hepatocytes obtained by CM2 and the Wnt/b-catenin activation
could also suggest a transformation of these cells into CSC. This
hypothesis is reinforced with data obtained in CM2-treated cells
related to an abnormal proliferation, higher PCNA expression, cell
cycle alteration and secondary spheroids formation. These results
suggest that in contrast to undifferentiated or CM1-treated cells,
CM2-treated cells conserve stemness capability. This capability to
form spheroids is intrinsic of stem cells or CSC. Sphere forming
ability is known to be one of properties of CSCs [33,34].
Secondary spheres formation after seeding cells at clonal density
confirms that spheres formation reflects auto-renewal rather than
cell aggregation. In addition the increased expression of CD13,
CD49e, CD133, CD166 or VEGFR2 in CM2-treated cells
suggests also similarities to CSC. Some proteins as CD13 or
CD49e participate in process of chemotaxis, invasion and
metastasis of malignant cells [35]. CD13 is an aminopeptidase N
with matrix metalloproteinase activity that has been shown to play
a role in tumor angiogenesis, invasion and metastasis, radiation
resistance, and antiapoptosis [36,37] and it has been involved with
human liver CSC [38]. Haraguchi et al showed that the
suppression of CD13 inhibited self renewal and the tumor
initiation ability of CD13
+cells [38]. CD49e, also known as
Figure 6. The activation of Wnt/b-catenin during hepatocyte differentiation is associated with the presence of related proteins to
tumoral phenotype. Relative abundance of specific proteins (DIGE analysis) in human mesenchymal stem cells undifferentiated after 21 days of
culture (UC21d) and in mesenchymal stem cells differentiated into hepatocytes with conditioned medium 1 (CM1) or 2 (CM2). B) Western blot
confirmation of the changes observed by DIGE analysis in the abundance of some proteins in CM1 and CM2 hepatocytes: Adenine phosphoriobosyl
transferase (APT), cathepsin B precursor (CATB), L-lactate dehydrogenase b chain (LDHB), transgelin (TGL2), tropomyosin b chain (TPM2) and nuclear
b-catenin. Tubulin and TFIIB were used as cytoplasm and nuclear loading control respectively.
doi:10.1371/journal.pone.0034656.g006
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expression is increased in the hepatocellular carcinoma cell lines
MHCC97 [39] and SMMC-7721 [35]. Angiogenesis is important
for tumor growth, and is regulated by vascular endothelial growth
factor (VEGF). Hepatocellular carcinoma is a solid tumor with
rich neovasculature and VEGFR2 overexpression has been
localized in tumoral hepatocytes [40]. CD133 is a CSC marker
associated with radioresistance and chemoresistance in various
cancers and has been also identified as specific antigenic marker of
liver CSC [41,42].
Finally, our proteomic analysis showed a higher presence of
hepatocellular carcinoma-related proteins, such as cathepsin b
precursor, cathepsin D precursor, adenine phosphoribosyl trans-
ferase, L-lactate dehydrogenase, triosephosphate isomerase, inor-
ganic pyrophosphatase or peptidyl prolyl cis-trans isomerase, in
CM2 treated cells compared to CM1 treated cells. A high
expression of these proteins has been observed in hepatic tumor
and metastasis [43,44,45]. Some of the detected proteins in this
study participate in processes associated with the pathogenesis and
the metastatic spread of hepatocellular carcinoma, such as cell
motility and invasion, metabolism and signal transduction.
Cathepsin-D has been reported to play an essential role in
multiple tumor progression steps, affecting cell proliferation,
angiogenesis, and apoptosis. Other reports also suggest that
cathepsin D is a key mediator in induced apoptosis [46,47].
Adenine phosphoribosyltransferase is an enzyme involved in the
purine nucleotide salvage pathway, which is up-regulated in
hepatocellular carcinoma and has been associated with Wnt/
b-catenin activation [30]. Tumor formation is generally linked to
increased activity of glycolytic enzymes, such as lactate dehydro-
genase b [45,43,48] or triosephosphate isomerase [45,49] and
both proteins have been shown to be increased in CM2 treated
cells in the present study. The reduction in LDH activity has been
reported to result in diminished tumorigenicity, demonstrating
that LDH plays a key role in tumor maintenance [50]. Peptidyl-
prolyl isomerase (Cyclophilin A) has been implicated in several
pathological processes, including hepatocellular carcinoma
[51,52]. Other studies have also showed the up-regulation of
inorganic pyrophosphatase during hepatocellular carcinoma [45].
In contrast, other proteins are down-regulated in tumoral
processes, including hepatocellular carcinoma. Tropomyosin b
chain, transgelin or annexin A5, with a lower expression in CM2-
treated cells compared to CM1-treated cells, are down-regulated
proteins in hepatocellular carcinoma. Tropomyosin plays a role of
stabilization of actin filaments and in the suppression of cellular
transformation in non muscle cells, such as hepatocytes [53].
Other studies showed a decreased expression of this protein in
hepatocellular carcinoma [54]. Transgelin is also a specific protein
of smooth muscle cells, but its involvement in tumoral processes as
a novel tumor suppressor protein has been documented. The loss
of transgelin is a characteristic signature of colon and prostate
carcinogenesis and its restoration suppresses colon tumorigenity in
vivo and in vitro [55]. Besides, the promoter regions of transgelin
are highly methylated in hepatocellular carcinoma [56]. Our study
shows that the expression of transgelin was significantly decreased
in CM2 vs. CM1 treated cells. Another protein with altered
expression in our study is annexin A5. Annexins belong to a family
of calcium-regulated phospholipid-binding proteins that has
various intra- and extracellular roles in a range of cellular
processes such as cell signalling, ion transport, cell division, and
apoptosis [57]. The expression of DnaJ homologous subfamily B
(member 11) was also decreased in CM2 vs. CM1 treated cells,
and the decrease of this anti apoptotic protein may participate in
the observed tumoral phenotype of CM2-treated cells.
In summary, our study demonstrates that Wnt/b-catenin down-
regulation is not necessary for hepatocyte differentiation of MSC.
We show for the first time a cross-talk between human bone marrow
MSC hepatocytes differentiation, Wnt/b-catenin pathway and a
tumoral phenotype. The activation of Wnt/b-catenin during human
MSC differentiation into hepatocytes is associated with abnormal
proliferation, expression of CSC markers, spheroid formation and
the generation of liver cells with tumoral characteristics, in contrast
to hepatocytes differentiated without Wnt/b-catenin activation.
Exploration of the differences between cancer stem cells from
normal stem cells is crucial not only for the understanding of tumor
biologybut also for the prevention ofpotential complicationsderived
from future liver therapies with human MSC.
Materials and Methods
Ethics Statement
This study was approved by the Reina Sofia University Hospital
Review Board. The procedures followed were in accordance with
the ethical standards of the ethic committee from Hospital Reina
Sofı ´a and with the Declaration of Helsinki. All samples were
collected after written informed consent.
Human mesenchymal stem cells (MSCs) isolation
Human bone marrow (BM) was aspirated from the iliac crest of
healthy donors. Fresh BM was cultured in flasks (FalconTM, BD
Pharmigen, Franklin Lakes, NJ) seeding 10 ml BM cells/cm
2 with
alpha-minimum essential medium (a-MEM) supplemented with
Table 3. Primers used for quantitative RT-PCR analyses.
Albumin (ALB) F: 59 TGA GAA AAC GCC AGT AAG TGA C 39
R: 59 TGC GAA ATC ATC CAT AAC AGC 39
a-Fetoprotein
(AFP)
F: 59 GCT TGG TGG TGG ATG AAA CA 39
R: 59 TCC TCT GTT ATT TGT GGC TTT TG 39
CK18
(KRT18)
F: 59 CCC GTC ACG CCC TAC AGA T 39
R: 59 ACC ACT TTG CCA TCC ACT ATC C 39
C/EBPa
(CEBPG)
F: 59 CCC GCC CGT GGT GTT ATT 39
R: 59 GGT TGC GTC AGT CCC GTG TA 39
Cytochrome P450
CYP3A5
F: 59 GAT CCC CTT GAA ATT AGA CAC G 39
R: 59 TTG AAA TCT CTG GTG TTC TGG 39
a1-antitrypsin
(SERPINA1)
F: 59 AAG GTG CCT ATG ATG AAG CGT 39
R: 59 GTG ATG CCC AGT TGA CCC A 39
Lrp5/6 F: 59 GCA GCC TTT CTT CCA CAC TC 39
R: 59 CTC CTG CCT TAC ACG TCC T 39
Frizzled-3
(FZD3)
F: 59 TGG AGC CAT TCC ACC CTA TG 39
R: 59 GAA CCT ACT GCA TTC CAT ATC 39
c-myc
MYC
F: 59 ACC ACC AGC AGC GAC TCT GAG GA 39
R: 59 CGT AGT TGT GCT GAT GTG TGG AGA 39
18S Ribosomal
RN18S1
F: 59 GTA ACC CGT TGA ACC CCA TT 39
R: 59 CCA TCC AAT CGG TAG TAG CG 39
doi:10.1371/journal.pone.0034656.t003
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Switzerland), 100 U/ml Penicillin, 0.1 mg/ml Streptomycin and
1 ng/ml of fibroblast growth factor-basic (FGF-b, Peprotech EC,
London, UK) [58]. Cells were allowed to adhere for 48 h and non-
adherent cells were washed out with phosphate-buffer saline (PBS)
100 mM pH 7,4 (Sigma-Aldrich, St Louis, MO). After 48 h, a-
MEM supplemented with 10% FBS and 1 ng/ml FGF-b was
added twice weekly. All cultures were maintained at 37uCi na
humidified atmosphere containing 5% CO2. When adherent cells
reached 90% confluence they were detached with 0.25% trypsin-
EDTA (BioWhittaker, Switzerland), washed twice with PBS,
centrifuged at 1800 rpm, 5 minutes and 4uC and replated in 6-
well plates (SPL life sciences, Korea) at 10
3 cells/cm
2 and cultured
under the same conditions.
In vitro hepatic differentiation
Two different differentiation protocols were applied to confluent
human MSCs for their differentiation into hepatocytes. An
explicative diagram is included in Supporting Information (Figure
S2). In the first protocol (conditioned medium 1, CM1), cells were
cultured in a-MEM containing 10% FBS, 20 ng/ml hepatocyte
growth factor(HGF) and 10 ng/ml fibroblast growth factor-7 for 21
days.Thesecondprotocol(conditionedmedium2,CM2)isbasedin
the article by Kuan der Lee [17]. Briefly, human MSCs were
previously treated with epidermal growth factor (EGF) 20 ng/ml
and FGF-b 10 ng/ml for 48 h. Then, 20 ng/ml HGF, 10 ng/ml
FGF-b and 0.61 g/L nicotinamide were added for one week.
Finally, cells were treated for fourteen days with 1 mM dexameth-
asone, 20 ng/ml oncostatin and 10 ml/ml ITS. Treatments were
refreshed 2–3 times per week. All cytokines were purchased from
Peprotech EC (Paris, France), nicotinamide and dexamethasone
were obtained from Sigma-Aldrich (St Louis, MO) and ITS from
BD Pharmigen (FranklinLakes,NJ,USA). Nuclear and cytoplasmic
proteins and RNA were collected at 7, 14 and 21 days of culture.
Flow Cytometry Analysis
For immunophenotype studies, basal and differentiated human
MSC were detached and stained with fluorescein- or phycoery-
thrin-coupled antibodies and analyzed with a FACSCalibur flow
cytometer (Becton, Dickinson). Anti-CD34-FITC, anti-CD45-PE
and anti-CD133 were purchased from Miltenyi Biotec (Berlin,
Germany), anti-CD73-PE, anti-CD90- PE and anti-CD166 were
from BD Pharmigen (Franklin Lakes, NJ), anti-CD13-FITC, anti-
CD44-FITC and anti-CD49e-FITC were from Beckman Coulter,
Inc (CA, USA), anti-CD105-FITC was from R&D Systems (MN,
USA), and anti-CD29-FITC, anti-CD184-PE and VEGFR2 were
from eBioscience, Ltd (London, UK).
Quantitative real time RT- PCR analysis
Total RNA was extracted following a modification of Chome-
zynski and Sacchi’s protocol with Trizol reagent Sigma-Aldrich (St
Louis,MO). Total RNA was quantifiedby spectrophotometry (ND-
1000, Nanodrop Tecnologies, DE, USA). One mg of total RNA was
treated with DNAse (DNAse kit, Sigma-Aldrich, St Louis, MO) and
complementary DNA was amplified using the QuantiTect Reverse
Transcripction kit (Qiagen, Hilden, Germany). Primers were
designated with the free Oligo 7 software and their sequences are
listed in Table 3. Quantitative real-time PCR was performed in a
Light cycler 480 (Roche Diagnostics, Basel, Switzerland).
Immunocytochemical analysis
Human MSCs were cultured on chamber slides (Nunc,
Rochester, NY, USA) for 21 days and then were fixed and treated
during 20 min with 0.01 M citrate buffer pH 6. Cells were
incubated for 1 h at room temperature with: anti-PCNA (1:75
dilution, Santa Cruz Biotechnologies, Santa Cruz, CA, USA), anti-
albumin (DakoCytomation Glostrup, Denmark, 1:2000 dilution),
anti-a-fetoprotein (R&D Systems, Minneapolis, MN, USA, 10 mg/
ml), anti-cytokeratin-19 (R&D Systems, Minneapolis, MN, USA,
10 mg/ml), or anti-a-1-antitrypsin (DakoCytomation Glostrup,
Denmark, 1:800 dilution) primary antibodies. HRP-labelled
polymer conjugated to secondary antibodies was used for
30 minutes at room temperature and diaminobenzidine was added
to detect positive staining. Finally, cells were counterstained with
hematoxylin (DakoCytomation Glostrup, Denmark). During all the
procedure three washes with PBS were performed after each step.
Confocal microscopy analysis
Undifferentiated and differentiated human MSCs were cultured
on chamber slides and, after the corresponding treatments; they
were fixed with 4% paraformaldehyde (Sigma-Aldrich) for
15 minutes at room temperature. Samples were then treated with
chilled methanol (220uC) for 10 min and washed in PBS (36, for
5 min) and then sequentially incubated for 60 minutes each with
anti-b-catenin (1:50, BD Pharmigen, Franklin Lakes, NJ) and anti-
mouse IgG-FITC (DakoCytomation Glostrup, Denmark). Between
incubations, slides werewashed withPBS+1% BSA(Sigma-Aldrich)
for 10 minutes. DAPI (Invitrogen, CA, USA) was used for nuclear
stain. Cells were examined by confocal fluorescence microscopy
using a confocal microscope (LSM 5 Exciter Carl Zeiss).
Cell count
The number of undifferentiated cells, CM1 and CM2-treated
cells was counted at 0, 7, 14 and 21 days of culture. Cells were
treated with Trypsin-EDTA (Sigma), inactivated with medium
plus FBS and washed with PBS. Trypan blue was used to measure
the cellular viability and the count was carried out with a
Neubauer chamber.
Cell cycle
For cell cycle, the different types of cells (undifferentiated, CM1
and CM2-treated cells) were harvested after 21 days of
differentiation. Cells were trypsinized and subsequently fixed in
70% cold ethanol overnight. After cells were centrifuged and
washed with Hank’s solution 16 (Sigma-Aldrich, St Louis, MO)
twice. Cells were lysated with DNA extraction buffer which
contained citric acid 0.1 M and anhydrous disodium phosphate
0.2 M (Sigma-Aldrich, St Louis, MO) for 5 minutes. After
incubation, cells pellets were resuspended in 100 ml staining buffer
which contining 50 mg/ml propidium iodine, 50 mg/ml RNase,
0.1% Triton-X-100 and 0.1 M EDTA in PBS (Sigma-Aldrich, St
Louis, MO). Cells were incubated for 30 min in darkness. Finally,
cells were resuspended in PBS and they were acquired at low
speed using FACScaliber (Becton Dickinson, CA, USA). Cell cycle
analysis was performed on FlowJo program based on the
mathematical algorithm of Watson (Becton Dickinson, CA, USA).
Spheroid formation assay
Figure S3 from Supporting Information section indicates the
followed steps for spheroids assay. After 21 days of culture, cells
were collected with Trypsin-EDTA and harvested at 50000 cell/
ml in low adherence plates (6 wells) with DMEM:H12 medium
without glutamine, antibiotics or serum and plus 20 ng/ml EGF
(Peprotech, NJ, USA), 10 ng/ml bFGF (Peprotech), B27 16
(Invitrogen, CA, USA) and insulin 100 IU (Novo Nordisk,
Bagsvaerd, Denmark). After 4 days of culture, spheres formation
Mesenchymal Stem Cells, Wnt and Liver Cancer
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trypsin- EDTA digestion was counted.
To analyze the number of secondary spheroids undifferentiated
cells, CM1 and CM2 treated cells were harvested at clonal dilution
(cell/ul) on low adherence plates. After 4 days of culture the
number of spheres was counted in an inverted microscope. Three
experiments were carried out and the data are expressed as mean
of number of spheres 6 standard deviation. Representative
microphotographs of secondary spheroids were taken in an
inverted microscope to 106.
To check 3-dimensional structure of spheroids, undifferentiated
cells, CM1 and CM2-treated cells were collected from plates and
stained with DAPI for 5 minutes. Subsequently cell were centrifuged
gentlely and resuspended in 15 ul of PBS. Spheroids’ mounting was
carried out according to the protocol described by Weiswald et al
[59]. For 3D reconstruction, a stack of confocal images was collected
through the spheroids with step size of 0.488 mm between adjacent
optical planes, starting from one pole of the spheroids. 360u 3D
projects plugging from ImageJ was used to generate a 3D animation.
Two-dimensional difference gel electrophoresis (2D-
DIGE) analysis
After acetone precipitation, protein samples (Control cells at 0
and 21 days of culture and hepatocytes obtained by CM1 or CM2)
were solubilized in 2-D DIGE sample buffer: 7 M urea, 2 M
thiourea, 4% CHAPS, 30 mM Tris, buffered to pH 8. Protein
concentration was determined using the Bradford’s assay (Bio-
Rad). Then, 50 mg protein was labelled with 400 pmol of CyDye
DIGE Fluor minimal dyes (GE Healthcare) and incubated on ice
in the dark for 30 min according to the manufacturer’s
instructions (Cy3, Cy5 for samples and Cy2 for internal control
consisting of a mixture composed by equal amounts of protein
from all samples). Paired samples were reverse-labeled in order to
prevent potential dye labeling bias. The reaction was stopped by
addition of 1 ml of 10 mM lysine and incubated on ice for 10 min.
Samples were cup-loaded onto IPG strips, 24 cm, pH 3–11NL
(GE Healthcare), and subjected to isoelectrofocusing (IEF) in
IPGphor
TM IEF System (GE Healthcare) according to the
manufacturer’s recommendations. Upon IEF, strips were incubat-
ed in equilibration buffer (50 mM Tris-HCl, pH 8.8, 6 M urea,
30% glycerol, 2% SDS, a trace of bromophenol blue), containing
0.5% DTT for 15 min and thereafter in the same buffer with 4.5%
iodoacetamide for 15 min. For the second dimension, strips were
loaded on top of 12.5% polyacrylamide gels and run (1 W/gel) for
12–14 h until the bromophenol blue dye reached the gel bottom-
end. Subsequently, 2D gels were scanned using a TyphoonTM
Trio Imager (GE Healthcare) at 100 mm resolution with lex/lem
of 488/520, 532/580, and 633/670 nm for Cy2, Cy3, and Cy5
respectively. The photomultiplier tube was set to ensure that the
maximum pixel intensity was between 90,000 and 99,000 pixels.
Image analysis was performed using DeCyder 6.5 software (GE
Healthcare) as described in the user’s manual. Three independent
experiments were performed for each experimental setup. Briefly,
the differential in-gel analysis module was used for spot detection,
spot volume quantification and volume ratio normalization of
different samples in the same gel. Then the Biological Variation
Analysis (BVA) module was used to match protein spots among
different gels and to identify protein spots that exhibit significant
differences. Manual editing was performed in the BVA module to
ensure that spots were correctly matched between different gels,
and to get rid of streaks and speckles. Differential expressed spots
were considered for MS analysis when the fold change was larger
than 1.2 and the p-value after T-test was below 0.05. Preparative
gels were run with 350 mg of protein following the same procedure
described above. Proteins were visualized by staining with SYPRO
Ruby Protein Gel Stain (Bio-Rad) and images were acquired with
a TyphoonTM Trio Imager using lex/lem of 532/560 nm.
Spots differentially represented were excised manually and gel
specimens were processed with a MassPrep station (Waters). In-gel
tryptic digestion was performed with 12.5 ng/ml trypsin in 50 mM
ammonium bicarbonate for 12 h at 37uC. The resulting peptides
were extracted with 5% formic acid, 50% acetonitrile. Samples
were then concentrated in a speed-vac before MS analysis.
Protein identification by LC-ESI-MS/MS analysis
Microcapillary reversed phase LC was performed with a
CapLCTM (Waters) capillary system. Reversed phase separation
of tryptic digests was performed with an Atlantis, C18, 3 mm,
75 mm610 cm Nano EaseTM fused silica capillary column
(Waters) equilibrated in 5% acetonitrile, 0.2% formic acid. After
injection of 6 ml of sample, the column was washed during 5 min
with the same buffer and the peptides were eluted using a linear
gradient of 5–50% acetonitrile in 30 min at a constant flow rate of
0.2 ml/min. The column was coupled online to a Q-TOF Micro
(Waters) using a PicoTip nanospray ionization source (Waters).
The heated capillary temperature was 80uC and the spray voltage
was 1.8–2.2 kV. MS/MS data were collected in an automated
data-dependent mode. The three most intense ions in each survey
scan were sequentially fragmented by CID using an isolation width
of 2.5 and relative collision energy of 35%. Data processing was
performed with MassLynx 4.0. Database searching was done with
ProteinLynx Global Server 2.1 (Waters) and Phenyx 2.2 (GeneBio,
Geneva, Switzerland) against Uniprot knowledgebase Release 12.3
consisting of UniprotKB/Swiss-Prot Release 54.3 and Uni-
protKB/TrEMBL Release 37.3 with 285.335 and 4.932.421
entries respectively. The search was enzymatically constrained for
trypsin and allowed for one missed cleavage site. Further search
parameters were as follows: no restriction on molecular weight and
isoelectric point; fixed modification, carbamidomethylation of
cysteine; variable modification, oxidation of methionine.
Preparation of cell lysates for Western Blot
Cytosolic extracts were obtained with a lysis buffer A, pH 7.9,
containing 10 mM Hepes, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT, 0.5 mM PMSF, 70 mg/ml Protease Inhibitor
Cocktail, 0.5% Igepal CA-630 (Sigma-Aldrich, St Louis, MO).
The suspension was centrifuged (13000 rpm, 3 min and 4uC) and
supernatant was stored at 280uC until used. Nuclear extracts were
obtained by incubating the pellet obtained as described above in a
lysis buffer B, pH7.9, containing 20 mM Hepes, 0.4 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 46 mg/
ml Protease Inhibitor Cocktail (Sigma-Aldrich, St Louis, MO).
Protein concentration was determined using the Bradford assay
(Bio-Rad Laboratories GmbH, Munich, Germany). For Western
Blot analyses, equal amounts of protein were loaded and
electrophoresed on 7% SDS-polyacrylamide gel (Invitrogen; CA,
USA). The protein was transferred to a nitrocellulose membrane
(Invitrogen; CA, USA), and blots were incubated in blocking
solution (Bio-Rad Laboratories GmbH, Munich, Germany).
Primary antibodies were diluted in TTBS+5% non fat dry milk
powder. Anti-b-catenin antibody (Cell Signaling, Boston, MA,
USA) was diluted 1:1000 before use and anti-TFIIB (1:500
dilution, Santa Cruz Biotechnology) was used as loading control of
nuclear extract. Other primary antibodies used were: anti-p53
(1:500) and anti-L-lactate dehydrogenase b chain (1:200) from
Santa Cruz Biotechnologies, anti-tropomyosin b chain (1:500),
adenine phosphoribosyltransferase (1:500) and Transgelin (1:2000)
that were purchased from Novus Biologicals Littleton, CO,
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from Abcam (Cambridge, UK) were performed. Blots were
immunolabeled using a horseradish peroxidase conjugated
secondary antibody and developed on autoradiographic film using
the ECL Plus Western Blotting Detection System from Amersham
Biosciences U.K. Limited (Little Chalfont, England).
Statistical analysis
Data are expressed as mean 6 SD. The difference between
means from two different groups was evaluated by performing a t
test and p values less than 0.05 were considered significant. The
data analysis was performed with SPSS.11 software.
Supporting Information
Figure S1 Movie showing the 3D structure of a repre-
sentative spheroid in CM2-treated cells.
(AVI)
Figure S2 Explicative diagram of both differentiation
protocols (CM1 and CM2).
(TIF)
Figure S3 Explicative diagram of spheroid formation
assay.
(TIF)
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